TIM-3 inhibitor / Partikula - LARVOL DELTA

Novel Immunotherapy Combos Target TIM-3 and PD-1/PD-L1 Networks (OncLive) - "'The theory here is that you can overcome I/O [immuno-oncology] resistance with a combination of a TIM-3 antibody with a PD-1/PD-L1 antibody,' Fred R. Hirsch, MD, PhD, said during the program....Findings from a meta-analysis published in Frontiers in Oncology in August 2020 illustrate the prognostic impact of TIM-3 expression, according to Hirsch....Paul A. Bunn Jr, MD, who served as moderator for the OncLive program, wondered about the rationale for not testing the combination in upfront settings, where the regimen might be more effective. He also questioned whether a patient who progressed on ICI therapy would respond to repeat administration of an ICI with an added therapy."

Media quote